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ABSTRACT
A cancer biomarker refers to a substance or process that is used as an indicative the presence of cancer in the body. A biomarker may be a molecule 
secreted by a tumor or a specific response of the body to the presence of cancer. Biomarkers are utilized in three elementary ways as a diagnostic tool, 
prognostic tool, and predictive tool. The screening tests employed are clinical and breast exams, mammography, hereditary screening, ultrasound, 
and attractive reverberation imaging. Biomarkers involved in breast cancer are human epidermal growth factor-2, estrogen receptor, progesterone 
receptor, Cyclin D1, and Cyclin E. Specific bioactive phytoconstituents used as anticancer include curcumin, genistein, resveratrol, isothiocyanates, 
silymarin, diallyl sulfisoxazole, lycopene, apigenin, and gingerol. Hence, this review indicates the study of screening methods, various biomarkers in 
breast cancer and phytoconstituents against breast cancer.
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INTRODUCTION
Breast cancer is considered to be one of the common cancer-related 
cause of death among females. Among women, it caused a major 
public health concern nearly 1 in 3 cancers diagnosed. It is one of the 
life-threatening diseases in a woman and they have to face during her 
lifetime. An increasing incidence of breast cancer reported over the 
past few decades and leads to the development of new anticancer drugs 
particularly from plants which showed a large amount of scientific 
evidence in lowering the risk of cancer [1].
Western European rates five-fold greater than Eastern/Middle Africa 
toward the incidence of breast cancer. The mortality rates also get 
differ in Southern/Western African which rates 3 times those of 
Eastern Asia [2]. By reductions in case fatality, higher incidence in 
developed countries largely attributable to mammographic screening 
and also there will be improved adjuvant therapy [3]. To manage the 
disease, it requires integration of clinical, pathological and biological 
parameters [4]. The risk stratification was considered to be prognostic 
histopathological variables which include tumor size, tumor grade, 
and lymph node status. Such individual prognostic parameters have 
been developed into the tumor, node and metastasis staging system [5] 
and Nottingham prognostic index [6,7]. In addition to this, various 
biomarkers (immunohistochemical markers) such as estrogen receptor 
alpha (ERα), progesterone receptor (PR), and the human epidermal 
growth factor receptor 2 (HER2) also represent mandatory elements 
for treatment [8,9].
The biomarker-based treatment implements learning points for lower 
resource settings. First, it involves successful delivery mandates 
technical and analytical consistency, as incorrect profiling of basic 
parameters is profoundly detrimental. This has been governed by 
authoritative guidance from the American Society of Clinical Oncology 
(ASCO) and College of American Pathologists [8,9] and quality 
assurance by the United Kingdom National External Quality Assessment 
Service [10]. Second, despite novel biomarkers, indices and signatures, 
few have clinical utility. So according to this, guidance for reporting of 
tumor marker studies [11] and a tumor marker utility grading system 
(ASCO) has been published [12,13]. Third, the international availability 
of biomarkers remains very uneven and confounded by inferences 
from developed health-care systems than specific evaluation in lower 
resource settings. BRCA1 is the leading mutation leading to breast 
cancer [14].
Determining the ER, PR, and HER2/neu receptor status in breast 
cancer becomes medical practice nowadays. Clinical trials have shown 
the survival advantage for patients with hormone receptor positive 
status by treatment with adjuvant hormonal or chemotherapeutic 
regimens [15].
In normal cells, this gene is involved in DNA repair, transcription 
regulation, and tumor suppression. To prevent cancer, it has been 
studied that diets rich in phytochemicals can reduce the risk of cancer 
by 20%. Plant natural product (phytoconstituent) has played an active 
role in generating a significant number of drug compounds in drug 
discovery program. Secondary metabolites and their derivatives from 
plants and other natural resources have been used for the treatment of 
various diseases [16].
In this review, established and emerging biomarkers, screening methods 
and various phytoconstituents were considered with reference to 
biological significance, clinical utility and resource implications.
CANCER BIOMARKER
“A cancer biomarker refers to a substance or process that is indicative 
of the presence of cancer in the body. A biomarker may be a molecule 
secreted by a tumor or a specific response of the body to the presence 
of cancer. It might be used to view how great that body response on 
medicine for an infection alternately condition. In addition, it is also 
called as an atomic marker [17].” Biomarkers about malignant might 
incorporate an expansive range from claiming biochemical entities, for 
example, nucleic acids, proteins, sugars, lipids, also little metabolites, 
cytogenetic also cytokinetic parameters and also entire malignant 
units discovered in the body liquid. A thorough understanding of the 
significance of every biomarker will be a chance to extremely critical not 
best for diagnosing the ailment reliably, as well as help in the decision of 
different restorative plan at present accessible that is liable will profit 
the patients [18]. Biomarkers are utilized within three elementary ways 
as a diagnostic tool, prognostic tool, and predictive tool [19].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Predictive carcinogenic biomarkers involve mutations in genes such as 
KRAS, p53, epidermal growth factor receptor, erbB2 for colorectal, liver, 
and pancreatic cancer; mutations in genes such as BRCA1, BRCA2 in 
breast, and ovarian cancer; abnormal methylation for malignant genes 
p16, CDKN2B, and p14ARF for forebrain cancer; hypermethylation for 
MYOD1, CDH1, and also CDH13 in cervical cancer; also hypermethylation 
of p16, p14, and RB1 for oral carcinoma [20].
Other illustrations of biomarkers [21]:
• Carcinogenic suppressors lost over malignancy. Examples: BRCA1 
and BRCA2
• RNA. Examples: mRNA and microRNA
• Proteins found previously, figure liquids or tissue. Examples: 
Prostate-specific antigen, furthermore CA-125.
SCREENING METHODS
Breast malignancy screening will be the restorative screening for 
asymptomatic, clearly solid ladies to breast malignancy previously, an 
endeavor to accomplish a sooner analysis. The supposition is that initial 
identification will enhance results. An amount for screening tests have 
been employed, including clinical and breast exams, mammography, 
hereditary screening, ultrasound, and furthermore attractive 
reverberation imaging [22].
Mammogram
A mammogram will be the proposed system for breast malignancy 
screening for those normal hazard populace. It will be that main 
screening modality demonstrated to decrease breast malignancy 
mortal sin. Time permits dangers to incorporate false negative 
outcomes also a false sense of security that might delay diagnosis; 
additional tests also tension connected with false sure comes about; 
and the truth that breast malignancy might be diagnosed for no change 
in the length or personal satisfaction about existence [23]. Higher 
the breast thickness will be connected with higher bosom disease 
danger previously, both premenopausal what’s more postmenopausal 
ladies [24]. On the other hand, ladies for greatly low densities need to 
be as of late indicated to hold a fundamentally more awful prognosis 
regardless of patients’ age, body mass index what’s more menopausal 
status [25]. Breast malignancy was troublesome and it should be 
identified through mammograms did ladies for secondary breast 
thickness in light of practical malignancy thick breast tissues bring 
a comparable presence ahead of the mammillary body. Likewise a 
result, higher breast thickness is connected with a higher rate of false 
negatives (missed cancers) [26].
Atomic breast imaging
Atomic breast imaging is an atomic pharmaceutical system that is at 
present under investigation. It demonstrates guaranteeing effects for 
imaging skin for thick breast tissue furthermore might have accuracies 
tantamount to magnetic resonance imaging (MRI). It might be superior 
to a mammogram to some people with thick breast tissue, identifying 
2 to 3 times more growth in this populace [27]. It, in any case, carries 
a more excellent danger about radiation harm making it improper to 
general breast malignancy screening [28]. It will be conceivable to 
decrease the measurement from claiming radiation utilized [29].
Ultrasonography
Therapeutic ultrasonic will be asymptomatic help with a mammogram. 
Including ultrasonic trying to ladies for thick breast tissue expands 
that identification from claiming breast cancer, as well as expands 
false [30]. There will be insufflated proof to help the utilization about 
ultrasonography to schedule screening in the normal danger populace. 
Ultrasonography ought not to be utilized likewise a solitary screening 
test. It might need a part likewise an assistant with mammogram 
previously, screening ladies for thick breasts, concerning illustration 
resolved toward a radiologist. Ultrasonography aides should recognize 
small, mammographically mysterious cancers; however, those generally 
sure predictive worth from claiming screening ultimo callous may be 
low.
Magnetic resonance imaging
Attractive reverberation imaging (MRI) need to be indicated will 
recognize growths not unmistakable ahead mammograms. Those 
Head quality for breast MRI may be its high negative predictive worth. 
A negative MRI could discount the vicinity of malignancy, and it will be a 
second degree for certainty, making it a phenomenal device around for 
screening in patients toward secondary hereditary danger alternately 
radiographically thick breasts, in pre-treatment arranging the place 
the degree of malady may be troublesome will determine through 
a mammogram. MRI might diagnose consider proliferative change, 
fibroadenomas, different normal discoveries in a glance, frequently 
eliminating those require to unreasonability and unnecessary biopsies 
alternately surgical methods. The spatial transient determination for 
breast MRI needs to be expanded for later years, making it could be 
allowed with recognizing alternately discount that vicinity for little in 
situ cancers, including ductal carcinoma in situ [31].
Signs for utilizing MRI to screening include solid family history about 
breast malignancy, patients with BRCA-1 alternately BRCA-2 oncogene 
mutations, assessment from claiming ladies for breast implants, 
historical backdrop from claiming past lumpectomy alternately 
breast biopsy surgeries, axillary metastasis for an obscure elementary 
carcinogenic, and exceptionally thick alternately scarred breast 
tissue [32]. MRI ought further bolstering not be utilized to screening 
the normal hazard populace. MRI might be utilized within particular 
condition likewise dictated toward a radiologist.
BRCA ANALYSIS
BRCA1 and BRCA2 mutations are the pre-eminent common cause of 
hereditary breast disease [33]. It was considered as human genes that 
produce tumor suppressor proteins, and it helps in repairing damaged 
DNA and play a role in ensuring the stability of the cell’s genetic 
material. BRCA 1 and BRCA 2 mutations cause 20-25% of hereditary 
breast cancer [34] and 5-10% of all breast cancers [35] and specific 
inherited mutations of these gene increases the risk of female breast 
and ovarian cancers, and they have been associated with increased 
risks of several additional types of cancer [36].
BIOMARKER IN BREAST CANCER
Human epidermal growth factor-2
HER-2 may be a paramount gene to subatomic focusing on medicine 
for breast malignant [37]. Determination of ER status about obtrusive 
breast carcinoma may be suitable as a prognostic and predictive figure, 
and ER+ predicts for a light of endocrine help for example, such that 
antiestrogen (tamoxifen) organization alternately ovarian concealment. 
Similarly, mankind’s epidermal development component receptor 2 
(HER2) positivity is handy for selecting focused on treatment with 
monoclonal immune response (trastuzumab) against HER2. Recently, 
microarray profiling from claiming obtrusive breast carcinoma need 
distinguished five different subtypes from claiming morphologically 
comparative breast malignancy (luminal A, luminal B, typical breast-like, 
HER2-overexpressing, furthermore the basal-like subtype), representing 
something like 15% for breast malignant situations furthermore 
portrayed toward cynicism for ER, PR, furthermore HER2, is connected 
with combative histology, poor prognosis, What’s more lethargy of the 
ordinary endocrine therapies, shorter survival, and BRCA1-related 
breast malignancy [38,39]. Exactly breast malignancy needs a shelter 
amount for HER2 receptors. The additional HER2 receptors animate 
those malignancy units will separate What’s more developed. When 
there would be higher levels of the HER2 protein done a breast cancer, 
it is known as HER2 certain breast malignant. The HER2/erbB2 gene, 
cell surface receptor tyrosine kinase is a pro-oncogene for signal 
transduction in cell development and division [40,41].
Estrogens receptor
Estrogens assume a huge part clinched alongside directing those 
development separation about normal, premalignant, harmful 
types, particularly breast epithelial cells, through interactional with 
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two atomic ER (ERα or ERß) [42]. The ER is a capable predictive 
and prognostic marker, as well as a productive target to that 
medication from claiming hormone-dependent breast tumor for 
antiestrogens [43]. Estrogen impacts would exert through two sorts for 
particular receptor: ERα and ERß [44]. These atomic receptors would 
ligand-dependent interpretation elements that intercede those living 
impacts about estrogens and antiestrogens. Estrogen, 17ß-estradiol 
(E2), assumes a noticeable part to mediating the maturation, 
proliferation, differentiation, apoptosis, inflammation, metabolism, 
homeostasis, and impacts the growth and improvement about breast 
malignant. ERs act principally toward directing the outflow for target 
genes whose promoters hold numerous particular successions called 
estrogen-responsive component [45].
Progesterone receptor
Progesterone will be an intense breast mitogen. An essential capacity 
from claiming progesterone/PR will be should intercede the monstrous 
development of epithelial-derived mammary alveoli (amelogenesis 
association for alveoli under lobules) throughout puberty and pregnancy 
on preparation to lactation. PRs are ligand-activated interpretation 
element parts of the steroid hormone receptor (SR) subfamily. PRs 
capacity not just as basic controllers about interpretation as well as 
on initiate indicator transduction pathways, a number about which are 
included for pro-proliferative indicating in the breast [46-48].
Cyclin D1
Cyclin D1 is a right on time light of mitogenic incitement to a few cell 
types, yet the outcomes of the modified statement of this gene clinched 
alongside mankind’s units about epithelial root stay undefined. We 
access the impacts for alterations for Cyclin D1 outflow in human breast 
malignant phones by generating T-47D units expressing mankind’s 
Cyclin D1 under the control of a zinc-responsive metallothionein 
promoter [49]. The division also answers from claiming eukaryotic 
phones are intercede toward an arrangement of facilitated occasions 
that create a “cell cycle collins [50].” The cycle comprises a mitotic 
stage (M phase) an interim between succeeding mitoses (interphase). 
The M period is made from claiming both mitosis and cytokinesis. 
There are two fundamental aggregations for the cycle: G1/S cyclin that 
intercedes G1/S transition including Cyclin A, Cyclin D, and Cyclin E; 
and G2/M cyclin that controls progression from G2 to M phase, for 
example, Cyclin B [51]. D-type cyclins cooperation with CDK4 and CDK6 
over promptly will work G1 phase, same time cycling prefers should 
CDK2 to late G1 phase [52]. Three D-type cyclins named Cyclin D1, D2, 
and D3, constantly on for which need aid prompted toward mitogens. 
Withdrawal the mitogens throughout G1 period makes fast debasement 
of D-type cyclin.
Cyclin E
Cyclin E will be a critical controller about cell cycle progression that 
together with the cyclin-dependent kinase (CDK) 2 may be vital for the 
G1, S move throughout those mammalian cell cycle [53,54]. It is a 50-kD 
cycle protein, as well as up to five low-molecular-weight isoforms 
of cyclin. These isoforms, which need that aminic terminus, would 
hyperactive, concerning illustration compared with that full-length 
protein, in phosphorylating substrates prompting progression starting 
with that G1 stage of the S period. Cycline and their reactant CDK 
accomplices act positively to propel a cell through those proliferative 
cycle [55,56]. Actuation from claiming cyclin-CDK complexes brings 
about a course of protein phosphorylation that eventually actuate cell 
cycle progression.
PHYTOCONSTITUENTS AGAINST BREAST CANCER
• Characteristic plants have been used to prevent also will treat 
different illnesses for many a considerable length of time [57]. There 
are phenomenal wellsprings of bioactive segments exerting their 
wellbeing valuable effects, furthermore often, these wellsprings are 
materials for gourmet nourishment utilizations. Specific bioactive 
segments starting with the plants need to be affirmed to their 
anticancer exercises [58]. These incorporate curcumin starting with 
turmeric, genistein starting with soybean, tea pack polyphenols 
starting with green tea, resveratrol from grapes, sulforaphane 
starting with broccoli, isothiocyanates from cruciferous vegetables, 
silymarin from milk thistle, diallyl sulfisoxazole from garlic, lycopene 
starting with tomato, rosmarinine corrosive starting with rosemary, 
apigenin starting with parsley, and also gingerol from gingers [59].
• Apigenin, a flavone present in parsley, celery, chamomile [60] and 
Egyptian plant Moringa peregrine exhibits cytotoxic exercises against 
breast malignancy mobile lines (MCF 7), colon mobile transport 
(HCT 116) [61]. Apigenin needs to be been demonstrated will 
make a standout among the gainful mixes for different phases about 
carcinogenesis [62].
• Curcumin’s anticancer impact is should actuate apoptosis over 
cancellous units without cytotoxic impacts looking into solid 
units [63]. Curcumin modulates development about carcinogenic 
phones through regulation of different mobile indicating pathways 
including cell burgeoning pathway (Cyclin D1, c-Myc) [64].
• Saffron is an zest from the bloom of the saffron crocus what’s more an 
nourishment colorant exhibit in the dry stigmas of the plant Crocus 
sativus saffron. Furthermore, its ethanolic extracts would also be 
accounted for the investigations around human lung malignancy 
pancreatic carcinoma cell transport skin carcinoma colorectal 
carcinoma units and breast malignant. Crocetin influences the growth 
of malignancy phones by hindering nucleic corrosive synthesis, 
upgrading antioxidative system, promoting apoptosis also upsetting 
development component indicating pathways.
• Gingerol needs to be concentrated onto its anticarcinogenic impacts 
for those malignant done colon, pancreas, breast, and ovarian. 
Gingerol needs to be exhibited antioxidant, anti-inflammation, 
and antitumor pushing properties (declines inducible nitric oxide 
synthase) [65].
CONCLUSION
In this review, we aimed to overview the breast cancer biomarkers 
and their development. A biomarker is an objectively measured 
characteristic that can be evaluated as an indicator of normal biological 
response, pathogenic processes, or therapeutic responses. Various types 
of screening methods are clinical and breast exams, mammography, 
hereditary screening, ultrasound, and attractive reverberation imaging. 
Certain plants and its constituents have been playing a major role in 
decreasing the activity of biomarkers such as Her-2, ER, PR, Cyclin-D1, 
and Cyclin E. Breast cancer is a heterogeneous disease with vast 
differences between patients in regard to treatment response and 
prognosis. Hence, strategies for individualizing care are required.
 “Keep your sunny side up, keep yourself beautiful,
 And indulge yourself !”
     -Betsey Johnson.
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